Pituitary-dependent Cushing's disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pasireotide is a second-generation somatostatin (SRIF) receptor ligand (SRL), approved for medical treatment of acromegaly and Cushing's disease (CD).
|
30483918 |
2019 |
Pituitary-dependent Cushing's disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
At present, the tumor-targeted pharmacological therapy of CD is concentrated on dopamine agonists (cabergoline) and somatostatin analogs (pasireotide) with varying efficacy, escape from response, and considerable side effects.
|
30535260 |
2019 |
Pituitary-dependent Cushing's disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pasireotide is a multi-receptor ligand somatostatin analogue approved for medical treatment of Cushing's disease and acromegaly.
|
31212595 |
2019 |
Pituitary-dependent Cushing's disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The only medication in this group approved for the treatment of CD is pasireotide, a somatostatin receptor ligand.
|
29765354 |
2018 |
Pituitary-dependent Cushing's disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pasireotide (SOM230, Signifor<sup>®</sup>) is a somatostatin analog approved in a subcutaneous formulation for the treatment of Cushing's disease.
|
29032486 |
2018 |
Pituitary-dependent Cushing's disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ACTH = adrenocorticotropic hormone; BRG1 = Brahma-related gene 1; CABLES1 = CDK5 and ABL1 enzyme substrate 1; CD = Cushing disease; CNC = Carney complex; DICER1 = cytoplasmic endoribonuclease III; EGFR = epidermal growth factor receptor; GR = glucocorticoid receptor; IL = interleukin; MEN = multiple endocrine neoplasia; miRNA = microRNA; POMC = proopiomelanocortin; SSTR = somatostatin receptor; USP8 = ubiquitin-specific protease 8.
|
30084690 |
2018 |
Pituitary-dependent Cushing's disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Such results are to be accounted for in development of pathway-specific somatostatin receptor agents in the treatment of hypercortisolism (Cushing's disease) and stress-related neuropsychiatric disorders.
|
27986975 |
2017 |
Pituitary-dependent Cushing's disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Subcutaneous (SC) injection of pasireotide, a somatostatin analog, is approved for the treatment of adults with Cushing's disease (CD) for whom pituitary surgery was unsuccessful or is not an option.
|
28289402 |
2017 |
Pituitary-dependent Cushing's disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
On the other hand, emerging drugs used in the treatment of CD, such as the novel somatostatin analog pasireotide, may have direct effects on glucose homeostasis regardless of control of cortisol excess.
|
28364356 |
2017 |
Pituitary-dependent Cushing's disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Octreotide, a somatostatin receptor type 2 (SSTR2)-preferring somatostatin analogue, has no effect on ACTH secretion in patients with Cushing's disease.
|
25011056 |
2014 |
Pituitary-dependent Cushing's disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This may explain why the sst₂-preferring somatostatin analog octreotide, compared with the multi-receptor-targeting somatostatin analog pasireotide, is generally ineffective in Cushing's disease.
|
24081741 |
2013 |
Pituitary-dependent Cushing's disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activation of somatostatin receptors (sstr1-5) by somatostatin and its analogues exerts an inhibitory effect on hormone secretion and provides the basis for the treatment of a range of endocrine diseases such as acromegaly, Cushing's disease and neuroendocrine tumors (NET).
|
22156600 |
2012 |
Pituitary-dependent Cushing's disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study suggests that somatostatin analogs more selective for SSTR5 and for SSTR1 and/or 2may have the therapeutic potential for medical treatment of CD and SCA, respectively, whereas clinical application of dopamine agonists selective for D2R is very limited in either CD or SCA.
|
19318729 |
2009 |